Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. [electronic resource]
Producer: 20140120Description: 2039-46 p. digitalISSN:- 1468-2060
- Adult
- Animals
- Benzamides -- therapeutic use
- Biopsy
- Bleomycin
- Disease Models, Animal
- Drug Evaluation, Preclinical -- methods
- Female
- Fibrosis
- Fos-Related Antigen-2 -- genetics
- Humans
- Imatinib Mesylate
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Middle Aged
- Molecular Targeted Therapy -- methods
- Piperazines -- therapeutic use
- Protein Kinase Inhibitors -- therapeutic use
- Protein Serine-Threonine Kinases -- genetics
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins c-abl -- metabolism
- Proto-Oncogene Proteins c-sis -- metabolism
- Pyrimidines -- therapeutic use
- Scleroderma, Systemic -- drug therapy
- Skin -- metabolism
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.